Piromelatine

Generic Name: Piromelatine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₆N_₂O_₄

CAS Number: 946846-83-9

Unique Ingredient Identifier: S3UN2146K9

Background: Piromelatine has been used in trials studying the treatment of Alzheimer's Disease.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Late-Stage Alzheimer's Pipeline Goes Beyond Amyloid and Tau

Eisai and Biogen's Leqembi and Eli Lilly's Kisunla are first anti-amyloid antibodies to slow Alzheimer's cognitive decline. 32 therapeutics in Phase III trials target neuroprotection, neurotransmitters, neurogenesis, inflammation, and proteinopathies. Leqembi and Kisunla have limited efficacy and notable side effects, prompting diverse opinions on clinical benefit. Next-gen therapeutics aim for easier administration and multiple pathways to treat Alzheimer's.

Related Clinical Trials:

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy